TSVT Profile
2seventy bio, Inc., headquartered in Cambridge, Massachusetts, operates as a pioneering cell and gene therapy company dedicated to advancing breakthrough treatments for cancer within the United States. Established in 2021, 2seventy bio focuses its efforts on the rigorous research, development, and eventual commercialization of innovative therapies aimed at addressing the complexities of cancer treatment.
At the core of its portfolio, 2seventy bio boasts a robust pipeline featuring promising products such as idecabtagene vicleucel (ide-cel), also known commercially as Abecma, and bb21217. These CAR-T cell therapies represent cutting-edge advancements in oncology, specifically tailored for the treatment of multiple myeloma, a challenging hematologic malignancy.
Collaboration plays a pivotal role in 2seventy bio's strategy for advancing therapeutic solutions. The company has established a strategic collaboration with Bristol-Myers Squibb Company, leveraging synergies and resources to accelerate the development and potential commercialization of its innovative therapies. This collaborative approach underscores 2seventy bio's commitment to fostering strategic partnerships that drive scientific progress and therapeutic innovation.
As 2seventy bio continues to expand its scientific capabilities and clinical pipeline, it remains dedicated to pioneering novel approaches that aim to transform the landscape of cancer care. With a steadfast focus on patient-centric innovation and rigorous scientific inquiry, 2seventy bio is poised to make significant strides in the field of cell and gene therapy, offering new hope to patients and healthcare providers alike in the fight against cancer.
|
